LifeMine Therapeutics
PrivateLast Round
Series E
Aug 6, 2026
Total Funding Raised
$558M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
LifeMine Therapeutics is a biotechnology company that leverages evolutionary insights from fungi to discover and develop novel precision medicines.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LifeMine Therapeutics Comparables
Compare LifeMine Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hexagon Bio | 79% | |
| Sirenas Marine Discovery | 79% | |
| Enveda Biosciences | 77% |
LifeMine Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Aug 6, 2026 | ||||
| Series C | Mar 23, 2022 | ||||
| Series B | Jan 7, 2021 | ||||
| Series A | Sep 18, 2017 |
Key People
Founding team and executive leadership
LifeMine Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boyu Capital | Series A |
| RA Capital Management | Series E |
| GV | Series C, Series A, Series E, Series B |
| Blue Pool Capital | Series C, Series A, Series B |
| ARCH Venture Partners | Series C, Series A, Series E, Series B |
| Bezos Expeditions | Series E |
| Fidelity Management & Research Company | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 6, 2026
$263M raised with participation from GV and ARCH Venture Partners.
- Mar 23, 2022
$175M round led by Fidelity Management & Research Company.
Recent news
Latest coverage and updates
- is_developingSep 3, 2026
LifeMine Therapeutics, Inc. is developing drug compound to prevent organ failure in transplant recipients on Sep 3rd '26.
- receives_financingAug 26, 2026
LifeMine Therapeutics, Inc. received financing of $188M in Series E on Aug 1st '26.
- receives_financingAug 26, 2026
LifeMine Therapeutics, Inc. received financing of $75M in Series D on Aug 26th '26.
LifeMine Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about LifeMine Therapeutics's valuation, stock price, and market status.
Is LifeMine Therapeutics a public or private company?
LifeMine Therapeutics is a private company.
What is the current stock price of LifeMine Therapeutics?
LifeMine Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is LifeMine Therapeutics worth (valuation)?
Valuation information for LifeMine Therapeutics is not publicly available.
Can I buy LifeMine Therapeutics stock?
LifeMine Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was LifeMine Therapeutics's last funding round?
LifeMine Therapeutics's most recent funding round was Series C on March 23, 2022.
Who are the main investors in LifeMine Therapeutics?
Key investors in LifeMine Therapeutics include Fidelity Management & Research Company, WuXi Healthcare Ventures, Milky Way Cap.
Will LifeMine Therapeutics IPO soon?
No public IPO plans have been announced for LifeMine Therapeutics.
How can I track LifeMine Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor LifeMine Therapeutics's secondary market activity and sign up for updates.